EE200100410A - Sulfamaathüdroksaamhappe metalloproteaasi inhibiitor - Google Patents
Sulfamaathüdroksaamhappe metalloproteaasi inhibiitorInfo
- Publication number
- EE200100410A EE200100410A EEP200100410A EEP200100410A EE200100410A EE 200100410 A EE200100410 A EE 200100410A EE P200100410 A EEP200100410 A EE P200100410A EE P200100410 A EEP200100410 A EE P200100410A EE 200100410 A EE200100410 A EE 200100410A
- Authority
- EE
- Estonia
- Prior art keywords
- sulphamate
- hydroxamic acid
- metalloprotease inhibitor
- acid metalloprotease
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11918199P | 1999-02-08 | 1999-02-08 | |
PCT/US2000/003061 WO2000046221A1 (en) | 1999-02-08 | 2000-02-07 | Sulfamato hydroxamic acid metalloprotease inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200100410A true EE200100410A (et) | 2002-12-16 |
Family
ID=22382974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200100410A EE200100410A (et) | 1999-02-08 | 2000-02-07 | Sulfamaathüdroksaamhappe metalloproteaasi inhibiitor |
Country Status (27)
Country | Link |
---|---|
US (3) | US6448250B1 (ko) |
EP (1) | EP1157021A1 (ko) |
JP (1) | JP2002536373A (ko) |
KR (1) | KR20010102000A (ko) |
CN (1) | CN1216056C (ko) |
AP (1) | AP2001002240A0 (ko) |
AR (1) | AR036585A1 (ko) |
AU (1) | AU775701B2 (ko) |
BG (1) | BG105788A (ko) |
BR (1) | BR0008440A (ko) |
CA (1) | CA2362230A1 (ko) |
CZ (1) | CZ20012849A3 (ko) |
EA (1) | EA005500B1 (ko) |
EE (1) | EE200100410A (ko) |
GE (1) | GEP20043238B (ko) |
HK (1) | HK1049660B (ko) |
HR (1) | HRP20010660A2 (ko) |
HU (1) | HUP0200119A3 (ko) |
IL (1) | IL144783A0 (ko) |
IS (1) | IS6039A (ko) |
MX (1) | MXPA01007987A (ko) |
NO (1) | NO20013850L (ko) |
PL (1) | PL350193A1 (ko) |
SK (1) | SK11352001A3 (ko) |
WO (1) | WO2000046221A1 (ko) |
YU (1) | YU57101A (ko) |
ZA (1) | ZA200106492B (ko) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
US6794511B2 (en) | 1997-03-04 | 2004-09-21 | G. D. Searle | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US6696449B2 (en) | 1997-03-04 | 2004-02-24 | Pharmacia Corporation | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
WO1999025687A1 (en) | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US20010039287A1 (en) * | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
US6511993B1 (en) | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
US6683093B2 (en) | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
CZ20032913A3 (cs) | 2001-05-11 | 2004-05-12 | Pharmaciaácorporation | Aromatické sulfonhydroxamáty a jejich použití jako inhibitorů proteázy |
US6683078B2 (en) | 2001-07-19 | 2004-01-27 | Pharmacia Corporation | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
GB0119396D0 (en) * | 2001-08-09 | 2001-10-03 | Celltech R&D Ltd | Hydroxamic acid derivatives |
GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
AU2003229883B2 (en) | 2002-04-03 | 2009-06-11 | Topotarget Uk Limited | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors |
CA2483314A1 (en) * | 2002-04-25 | 2003-11-06 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
US20050209278A1 (en) * | 2002-04-25 | 2005-09-22 | Mcdonald Joseph J | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
JP2006502980A (ja) * | 2002-06-25 | 2006-01-26 | ファルマシア・コーポレーション | アリールスルホニルヒドロキサム酸およびアミド誘導体、ならびにプロテアーゼ阻害薬としてのそれらの使用 |
GB0216382D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
MXPA05005474A (es) * | 2002-11-25 | 2005-07-25 | Pharmacia Corp | Acidos y amidas heteroarilsulfonilmetil hidroxamicos y su uso como inhibidores de proteasas. |
EP1594459B1 (en) | 2002-12-30 | 2010-02-17 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
CA2513246A1 (en) | 2003-01-17 | 2004-08-05 | Topotarget Uk Limited | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors |
US20050043533A1 (en) * | 2003-03-25 | 2005-02-24 | Babiak Kevin A. | Process for making alpha-substituted hydroxamic acids |
GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
EP1743638A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Pharmaceutical formulations of substituted pyrazoline compounds |
CA2634701C (en) * | 2005-12-21 | 2014-07-29 | Decode Genetics Ehf | Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation |
JP2010513272A (ja) | 2006-12-14 | 2010-04-30 | メルク エンド カムパニー インコーポレーテッド | アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法 |
WO2009075692A2 (en) | 2007-05-14 | 2009-06-18 | Invista Technologies S.A.R.L. | High efficiency reactor and process |
WO2013039851A1 (en) | 2011-09-12 | 2013-03-21 | Mallinckrodt Llc | Optical agents for imaging and visualization of matrix metalloproteinase enzymes |
WO2018037254A1 (en) * | 2016-08-24 | 2018-03-01 | Tfchem | Difluorinated compounds as depigmenting or lightening agents |
WO2020006384A1 (en) | 2018-06-29 | 2020-01-02 | Loyola University Of Chicago | Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy |
CA3115038A1 (en) | 2018-10-04 | 2020-04-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1067965A (en) | 1912-10-31 | 1913-07-22 | C T Ham Mfg Company | Vehicle-lamp. |
GB1067965A (en) * | 1965-01-22 | 1967-05-10 | Beecham Group Ltd | Penicillins, esters, amides and salts thereof |
US4595700A (en) | 1984-12-21 | 1986-06-17 | G. D. Searle & Co. | Thiol based collagenase inhibitors |
US4882434A (en) | 1986-10-29 | 1989-11-21 | Takeda Chemical Industries, Ltd. | Gamma-lactonecarboxylic acid derivatives and their use as antibacterial agents or intermediates |
DE3811777A1 (de) * | 1988-04-08 | 1989-10-19 | Hoechst Ag | Heterocyclisch substituierte alkyl- und alkenylsulfonylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als herbizide oder pflanzenwachstumsregulatoren |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
JP3122161B2 (ja) | 1991-05-16 | 2001-01-09 | 武田薬品工業株式会社 | γ−ラクトン免疫抑制剤 |
DE69309047T2 (de) | 1992-04-07 | 1997-09-11 | British Biotech Pharm | Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren |
US5376664A (en) | 1992-07-27 | 1994-12-27 | The Du Pont Merck Pharmaceutical Company | Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9307956D0 (en) | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
GB9320660D0 (en) | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
CA2175057A1 (en) | 1993-11-04 | 1995-05-11 | Robert P. Lenk | Multilamellar liposomal arachidonic acid metabolite formulations |
GB9323165D0 (en) | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
GB9416897D0 (en) | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
EP0784629B1 (en) | 1994-10-05 | 1999-04-28 | Darwin Discovery Limited | Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases |
ATE283264T1 (de) | 1995-12-08 | 2004-12-15 | Agouron Pharma | Zwischenprodukte zur herstellung von metallproteinasehemmern |
PT780386E (pt) | 1995-12-20 | 2003-02-28 | Hoffmann La Roche | Inibidores de metaloprotease de matriz |
WO1997024117A1 (en) | 1996-01-02 | 1997-07-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds |
ATE272636T1 (de) * | 1996-06-20 | 2004-08-15 | Schering Corp | Naphthyridine die den rezeptor il-4 und den faktor g-csf beeinflussen |
ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
SK115899A3 (en) | 1997-02-27 | 2000-05-16 | American Cyanamid Co | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
WO1999025687A1 (en) * | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
IL135921A (en) | 1997-11-12 | 2005-08-31 | Darwin Discovery Ltd | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
US20010039287A1 (en) | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
GB9725782D0 (en) * | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
IL127496A0 (en) | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
GB9801690D0 (en) * | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
CN1213021C (zh) | 1998-02-19 | 2005-08-03 | 惠氏控股公司 | 作为基质金属蛋白酶抑制剂的 n -羟基- 2 - (烷基、芳基或杂芳基硫烷基、亚磺酰基或磺酰基 ) - 3 -取代的烷 |
JP2002533387A (ja) | 1998-12-23 | 2002-10-08 | ジー.ディー.サール & カンパニー | 腫瘍治療の複合療法としてインテグリン拮抗物質と一つ以上の抗腫瘍剤を使用する方法 |
-
2000
- 2000-02-07 US US09/499,276 patent/US6448250B1/en not_active Expired - Fee Related
- 2000-02-07 EA EA200100867A patent/EA005500B1/ru not_active IP Right Cessation
- 2000-02-07 GE GEAP20006101A patent/GEP20043238B/en unknown
- 2000-02-07 AP APAP/P/2001/002240A patent/AP2001002240A0/en unknown
- 2000-02-07 KR KR1020017010040A patent/KR20010102000A/ko not_active Application Discontinuation
- 2000-02-07 JP JP2000597291A patent/JP2002536373A/ja active Pending
- 2000-02-07 CN CN008060339A patent/CN1216056C/zh not_active Expired - Fee Related
- 2000-02-07 AU AU27574/00A patent/AU775701B2/en not_active Ceased
- 2000-02-07 EP EP00905996A patent/EP1157021A1/en not_active Withdrawn
- 2000-02-07 PL PL00350193A patent/PL350193A1/xx not_active Application Discontinuation
- 2000-02-07 BR BR0008440-9A patent/BR0008440A/pt not_active IP Right Cessation
- 2000-02-07 IL IL14478300A patent/IL144783A0/xx unknown
- 2000-02-07 EE EEP200100410A patent/EE200100410A/xx unknown
- 2000-02-07 MX MXPA01007987A patent/MXPA01007987A/es unknown
- 2000-02-07 CA CA002362230A patent/CA2362230A1/en not_active Abandoned
- 2000-02-07 YU YU57101A patent/YU57101A/sh unknown
- 2000-02-07 WO PCT/US2000/003061 patent/WO2000046221A1/en not_active Application Discontinuation
- 2000-02-07 HU HU0200119A patent/HUP0200119A3/hu active IP Right Revival
- 2000-02-07 SK SK1135-2001A patent/SK11352001A3/sk unknown
- 2000-02-07 CZ CZ20012849A patent/CZ20012849A3/cs unknown
- 2000-02-08 AR ARP000100538A patent/AR036585A1/es unknown
-
2001
- 2001-06-19 US US09/884,548 patent/US6372758B1/en not_active Expired - Fee Related
- 2001-08-07 BG BG105788A patent/BG105788A/bg unknown
- 2001-08-07 NO NO20013850A patent/NO20013850L/no not_active Application Discontinuation
- 2001-08-07 IS IS6039A patent/IS6039A/is unknown
- 2001-08-07 ZA ZA200106492A patent/ZA200106492B/en unknown
- 2001-09-07 HR HR20010660A patent/HRP20010660A2/hr not_active Application Discontinuation
-
2002
- 2002-02-26 US US10/084,713 patent/US6492367B1/en not_active Expired - Fee Related
-
2003
- 2003-02-07 HK HK03100924.8A patent/HK1049660B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO20013850L (no) | 2001-09-19 |
JP2002536373A (ja) | 2002-10-29 |
EP1157021A1 (en) | 2001-11-28 |
EA005500B1 (ru) | 2005-02-24 |
AU775701B2 (en) | 2004-08-12 |
BG105788A (bg) | 2002-02-28 |
EA200100867A1 (ru) | 2002-04-25 |
HK1049660B (zh) | 2006-05-12 |
PL350193A1 (en) | 2002-11-18 |
HUP0200119A3 (en) | 2003-04-28 |
CN1362954A (zh) | 2002-08-07 |
AU2757400A (en) | 2000-08-25 |
SK11352001A3 (sk) | 2002-09-10 |
KR20010102000A (ko) | 2001-11-15 |
CN1216056C (zh) | 2005-08-24 |
US6492367B1 (en) | 2002-12-10 |
AP2001002240A0 (en) | 2001-09-30 |
NO20013850D0 (no) | 2001-08-07 |
AR036585A1 (es) | 2004-09-22 |
HK1049660A1 (en) | 2003-05-23 |
CZ20012849A3 (cs) | 2002-05-15 |
HRP20010660A2 (en) | 2005-02-28 |
YU57101A (sh) | 2005-06-10 |
IL144783A0 (en) | 2002-06-30 |
ZA200106492B (en) | 2003-05-07 |
BR0008440A (pt) | 2002-03-26 |
US6372758B1 (en) | 2002-04-16 |
WO2000046221A1 (en) | 2000-08-10 |
MXPA01007987A (es) | 2002-04-24 |
HUP0200119A2 (en) | 2002-06-29 |
IS6039A (is) | 2001-08-07 |
US6448250B1 (en) | 2002-09-10 |
CA2362230A1 (en) | 2000-08-10 |
GEP20043238B (en) | 2004-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200100410A (et) | Sulfamaathüdroksaamhappe metalloproteaasi inhibiitor | |
NO20015543L (no) | Aromatisk sulfonhydroksamsyre-metalloproteaseinhibitor | |
DE60002193D1 (de) | Metalloprotease inhibitoren | |
NO20002469L (no) | Aromatisk sulfonhydroksamsyre-metalloproteaseinhibitor | |
NO20000877L (no) | Forbedret syrekorrosjonsinhibitor | |
ATE325791T1 (de) | Hydroxypipecolate-hydroxamsäure-derivative als mmp inhibitoren | |
NO20013963L (no) | Aromatiske sulfonhydroksaminsyre-metallproteaseinhibitor | |
NO993587D0 (no) | Sulfonamid-metalloprotease-inhibitorer | |
NO20014243D0 (no) | Dihetero-substituerte metalloprotease inhibitorer | |
DE60043730D1 (de) | Arylsulfonamid-substituierte hydroxamsäure-derivate | |
NO20014242L (no) | Alkenyl- og alkynyl-inneholdende metalloprotease inhibitorer | |
DE60008548D1 (de) | Hydroxamsäurederivate als matrix-metalloproteinase-inhibitoren | |
IL139248A0 (en) | Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors | |
DE60012303D1 (de) | Alkinylische hydroxamsäureverbindungen als tace inhibitoren | |
DK1047665T3 (da) | Matrix metalloprotease inhibitorer | |
PL357084A1 (en) | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | |
NO20024481D0 (no) | Difluorbutyrsyre metalloproteaseinhibitorer | |
GB0026133D0 (en) | Hydroxamic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH1A | Change of representative |